Department of Biotechnology, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala, Haryana, 133207, India.
School of Chemical Sciences, Central University of Gujarat, Gandhinagar, Gujarat, India.
Pharmacol Rep. 2023 Aug;75(4):817-837. doi: 10.1007/s43440-023-00506-z. Epub 2023 Jun 24.
The earliest documented COVID-19 case caused by the SARS-CoV-2 coronavirus occurred in Wuhan, China, in December 2019. Since then, several SARS-CoV-2 mutants have rapidly disseminated as exemplified by the community spread of the recent omicron variant. The disease already attained a pandemic status with ever-dwindling mortality even after two and half years of identification and considerable vaccination. Aspergillosis, candidiasis, cryptococcosis and mucormycosis are the prominent fungal infections experienced by the majority of SARS-CoV-2 high-risk patients. In its entirety, COVID-19's nexus with these fungal infections may worsen the intricacies in the already beleaguered high-risk patients, making this a topic of substantial clinical concern. Thus, thorough knowledge of the subject is necessary. This article focuses on the concomitant fungal infection(s) in COVID-19 patients, taking into account their underlying causes, the screening methods, manifested drug resistance, and long-term effects. The information and knowledge shared herein could be crucial for the management of critically ill, aged, and immunocompromised SARS-CoV-2 patients who have had secondary fungal infections (SFIs).
最早有记录的由严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引起的 COVID-19 病例发生在中国武汉，时间是 2019 年 12 月。此后，几种 SARS-CoV-2 突变体迅速传播，最近的奥密克戎变体就是社区传播的一个例子。尽管已经识别出这种疾病并进行了大量疫苗接种，但它仍已达到大流行状态，死亡率不断下降。曲霉菌病、念珠菌病、隐球菌病和毛霉菌病是大多数 SARS-CoV-2 高危患者经历的主要真菌病。总的来说，COVID-19 与这些真菌感染的关系可能会使已经陷入困境的高危患者的情况更加复杂，这是一个值得关注的临床问题。因此，对这个问题有透彻的了解是必要的。本文重点关注 COVID-19 患者同时发生的真菌感染，考虑其根本原因、筛查方法、表现出的耐药性和长期影响。本文所分享的信息和知识对管理患有继发真菌感染（SFIs）的危重、老年和免疫功能低下的 SARS-CoV-2 患者至关重要。
